Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy

Nasser, Nicola J.; Wang, Yinkun; Borg, Jette; Saibishkumar, Elantholi P.

doi:10.1016/j.brachy.2014.01.007

Cited by 23 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data show that the CTV in postimplant prostate dosimetry is larger than that of the preimplant planning. This is mainly because of prostatic edema (11). The radiation coverage of the prostate at 1 month dosimetry was good in 192 patients (97%), whereas good CTV dose coverage was attained in only 165 patients (83%).…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 83%

“…Moreover, there are no clear guidelines to evaluate the quality of CTV dosimetry. Recently, we have shown that there are significant differences in dose coverage of different sectors of the prostate between preplan and postimplant dosimetry (11).…”

Section: Introductionmentioning

confidence: 99%

Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Although other studies have reported that prostate volume also affects D 90 , our study did not find this correlation to be statistically significant, likely because all of our patients had a prostate volume < 50 cc. Previous studies analyzing implant quality have reported a tendency for lower doses to be delivered anteriorly as compared to the posterior prostate in patients treated with LDR brachytherapy [19, 20]. In a multi-institutional analysis of 4547 patients, Merrick et al .…”

Section: Discussionmentioning

confidence: 99%

The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy

Echevarria

Naghavi

Venkat

et al. 2016

jcb

View full text Add to dashboard Cite

PurposeLow-dose-rate (LDR) brachytherapy has been established as an effective and safe treatment option for men with low and intermediate risk prostate cancer. In this retrospective analysis, we sought to study the effect of body mass index (BMI) on post-implant dosimetric quality.Material and methodsAfter institutional approval, records of patients with non-metastatic prostate cancer treated in Puerto Rico with LDR brachytherapy during 2008-2013 were reviewed. All patients were implanted with 125I seeds to a prescription dose of 145 Gy. Computed tomography (CT) based dosimetry was performed 1 month after implant. Patients with at least 1 year of prostate-specific antigen (PSA) follow-up were included. Factors predictive of adequate D90 coverage (≥ 140 Gy) were compared via the Pearson χ2 or Wilcoxon rank-sum test as appropriate.ResultsOne-hundred and four patients were included in this study, with 53 (51%) patients having a D90 ≥ 140 Gy. The only factor associated with a dosimetric coverage detriment (D90 < 140 Gy) was BMI ≥ 25 kg/m2 (p = 0.03). Prostate volume (p = 0.26), initial PSA (p = 0.236), age (p = 0.49), hormone use (p = 0.93), percent of cores positive (p = 0.95), risk group (p = 0.24), tumor stage (p = 0.66), and Gleason score (p = 0.61) did not predict D90.ConclusionsIn this study we show that BMI is a significant pre-implant predictor of D90 (< 140 Gy vs. ≥ 140 Gy). Although other studies have reported that prostate volume also affects D90, our study did not find this correlation to be statistically significant, likely because all of our patients had a prostate volume < 50 cc. Our study suggests that in patients with higher BMI values, more rigorous peri-implant dosimetric parameters may need to be applied in order to achieve a target D90 > 140 Gy.

show abstract

“…The majority of prostate cancers, however, occur in the peripheral zone, and the WP dosimetric parameters do not account for the zonal anatomy of the prostate nor capture the heterogeneity in dose distribution within the prostate [7,8]. Herein, the influence of zone-specific dosimetry on rates of biochemical failure and toxicity is described.…”

Section: Purposementioning

confidence: 99%

Influence of Zonal Dosimetry on Prostate Brachytherapy Outcomes

Hong

Reddy

Wilkinson

et al. 2014

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy

Cited by 23 publications

References 28 publications

Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer

Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer

The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy

Influence of Zonal Dosimetry on Prostate Brachytherapy Outcomes

Contact Info

Product

Resources

About